WebAug 22, 2024 · For relative changes versus a baseline value (nine studies), cutoff values ranged from 2.3% to 15.9%, with a greater decrease linked to a 16-fold higher risk of CTRCD (OR, 15.82; 95% CI, 5.84-42.85; area under the HSROC, 0.86; 95% CI, 0.83-0.89). The cut-off value reported varied widely across studies. Last, funnel plot asymmetry … WebCTRCD may progress to heart failure over time.2 The incidence and degree of CTRCD depends on type of the used cancer drug, cumulative dose and (pre-)existing cardiovascular comorbidities.3. Currently, …
Prognostic Value of GLS for Early Prediction of Cardiotoxic ...
WebMay 7, 2024 · CTRCD should be monitored in patients treated with ICIs by cardiac biomarkers and echocardiography, including LV-GLS. ICIs may increase the risk of CTRCD when used with cardiotoxic agents. Cancer Therapy-Related Cardiac Dysfunction in Patients Treated with a Combination of an Immune Checkpoint Inhibitor and Doxorubicin WebAbstract. Cancer therapeutics-related cardiac dysfunction (CTRCD) has become a leading cause of morbidity and mortality for cancer survivors, with the mortality rate for patients with CTRCD reportedly being as high as 60% by 2 years after treatment. Although early detection of subclinical left ventricular (LV) dysfunction is essential for ... northern lights tours from reykjavik
一般社団法人日本心エコー図学会
WebJul 29, 2024 · Cancer therapy-related cardiac dysfunction (CTRCD) is one of the most feared and undesirable side effects of chemotherapy, occurring in approximately 10% of … WebOct 3, 2024 · Metastatic breast cancer patients, who develop refractory CTRCD during or after anthracycline chemotherapy and/or HER2 targeted therapies were prospectively included in our study and treated with empagliflozin 10mg/day on top of their current HF therapies. Refractory CTRCD was defined as symptomatic HF in patients treated with … northern lights treeline svg